Safety and Immunogenicity of ASO3(B) Adjuvanted Split Virion Versus Non-adjuvanted Whole Virion H1N1 Influenza Vaccine in UK Children Aged 6 Months-12 Years: Open Label, Randomised, Parallel Group, Multicentre Study

This article, published through Online First of the British Medical Journal, details a study wherein researchers evaluated the safety, tolerability, and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in children aged 6 months to 12 years in the United Kingdom. Results showed the adjuvanted vaccine to be more reactogenic, more immunogenic, and to elicit higher seroconversion rates in children less than three years of age than the non-adjuvanted whole virion H1N1 influenza vaccine.

Author(s): Waddington CS, Walker WT, Oeser C, et al.

Published: 2010

  • Visit web page (English)

    (Located at www.bmj.com)

    Citation: Waddington CS, Walker WT, Oeser C, et al. Safety and Immunogenicity of ASO3(B) Adjuvanted Split Virion Versus Non-adjuvanted Whole Virion H1N1 Influenza Vaccine in UK Children Aged 6 Months-12 Years: Open Label, Randomised, Parallel Group, Multicentre Study. British Medical Journal. 2010;340:c2649.